New 340B Rebate Pilot Program Proposed by HRSA

You might care about this because the Health Resources and Services Administration, known as HRSA, is planning a big change for a part of the 340B drug discount program. They are introducing a new pilot program called the 340B Rebate Model Pilot Program. This program is a different way for certain drug manufacturers to make sure they offer drugs at the special 340B price. Instead of giving an upfront discount, manufacturers will use a rebate system for a specific group of drugs sold to hospitals and clinics, known as covered entities. HRSA has asked the Office of Management and Budget to approve its plan to collect information for this pilot. This includes gathering applications from drug manufacturers who want to join, sales data from these manufacturers for monitoring, and specific patient data from covered entities so they can get their rebates. HRSA previously asked for public comments on this information collection plan. They received 180 comments from a wide range of groups, including hospitals, pharmacies, and manufacturers. Many comments discussed worries about financial problems, the impact on patient care, and legal questions. However, HRSA said these specific concerns were not about the "burden" of collecting information, which is what they were asking about at the time. Those broader concerns will be handled in a separate announcement later. HRSA acknowledges that covered entities have pointed out potential administrative work, operational changes, and system updates required to submit data to manufacturers. Despite these concerns, HRSA believes its estimate of 5 hours per week for covered entities to comply is reasonable, based on their task-based method and the limited scope of the pilot. What makes this pilot program particularly interesting is that it represents a shift in how the 340B drug discount program might operate. For years, the program has primarily relied on upfront discounts. Moving to a rebate model, even for a limited set of drugs, is a big step. This change could affect how covered entities manage their money and how they access discounted medications. The document shows there is a clear disagreement between HRSA and many healthcare providers about the actual effort needed to participate in this new system. Covered entities say the proposed data collection will require a lot more staff, new computer systems, and ongoing checking of information. They say HRSA has underestimated the time and resources this will take. HRSA, however, believes that many of the needed data elements are already collected by these entities and that existing systems or automation can help reduce the workload. This debate highlights the challenges of implementing new rules in a complex healthcare system and finding a balance between regulation and practical operations. This pilot could set a precedent for how future drug pricing and discount programs are managed. This legal document would be most interesting to several groups. Drug manufacturers, especially those involved in the Medicare Drug Price Negotiation Program for 2026 and 2027, will want to understand the requirements for participating in this new rebate pilot. Hospitals, health systems, community health centers, and other covered entities that participate in the 340B program will find this very relevant. They need to know about the new data submission rules and the potential impact on their finances and operations. Healthcare administrators and compliance officers at these organizations will need to grasp the details to ensure their facilities can meet the new requirements. Policy experts and legal professionals who focus on healthcare law and drug pricing will also be keen to follow this development. Finally, patient advocacy groups and anyone interested in how drug costs and access to healthcare services are affected by government policies will find this information important. The outcome of this pilot could influence future policies and the broader healthcare landscape.